Core Viewpoint - KO Gold Inc. has announced an extension of the expiry date for certain warrants, allowing investors to purchase up to 3,363,772 common shares at $0.40 per share, now expiring on January 10, 2027, instead of January 10, 2026 [1] Group 1: Company Overview - KO Gold Inc. is a Canadian junior exploration company listed on the CSE under the ticker "KOG" [2] - The company's strategy focuses on acquiring and exploring gold properties in the Otago Gold District, New Zealand, with four 100%-owned prospecting and exploration permits covering a total area of 400 km² [2] - The Smylers, Hyde, and Glenpark exploration permits are located near OceanaGold's Macraes Gold Mine, while the Carrick EP is near the historic Carrick Goldfield, which is considered a promising gold deposit [2] - KO Gold has invested over C$3 million in exploration and drilling activities in the Otago Gold District over the past five years [2]

Core Viewpoint - Noble Mineral Exploration Inc. has successfully completed a non-brokered private placement, raising approximately $1.03 million to fund exploration activities in Ontario [2][5]. Private Placement - Noble raised gross proceeds of approximately $1,027,997.94 through the issuance of 17,133,299 flow-through common share units priced at $0.06 per unit [2]. - Each flow-through unit consists of one common share and one-half non-flow-through common share purchase warrant, with full warrants exercisable for two years at an exercise price of $0.10 per share [2]. - The company paid approximately $43,050 in cash commissions and issued 647,497 broker warrants, each exercisable for two years at an exercise price of $0.06 per share [3]. Regulatory Approvals - The private placement has received conditional approval from the TSX Venture Exchange and is subject to final approval [4]. Use of Proceeds - The proceeds from the private placement will be utilized for exploration expenditures on the company's properties located in Ontario [5]. Extension of Warrants - Noble has extended the term of 7,933,333 common share purchase warrants, which will now expire in November 2027 and December 2027 [6]. - Final approval for the extension of the warrants has been received from the Exchange [6]. Company Overview - Noble Mineral Exploration Inc. is a Canadian junior exploration company with holdings in various nickel and gold exploration properties [8]. - The company holds mineral and/or exploration rights in approximately 70,000 hectares in Northern Ontario and 24,000 hectares in Quebec [9]. - Notable projects include Project 81, which hosts drill-ready targets for gold, nickel-cobalt, and base metals [10].

Core Viewpoint - Izotropic Corporation is initiating a non-brokered private placement to raise up to $300,000 through the sale of 1,200,000 units at $0.25 each, with each unit comprising one common share and one transferable warrant [1][2] Group 1: Private Placement Details - The offering will consist of up to 1,200,000 units priced at $0.25 each, aiming for gross proceeds of up to $300,000 [1] - Each unit includes one common share and one warrant, allowing the holder to purchase an additional share at $0.50 for three years [1] - Proceeds from the offering will be allocated for general working capital [2] Group 2: Warrant Extension - The company has extended the expiry date of 2,841,325 outstanding share purchase warrants from September 20, 2025, to September 20, 2026, while maintaining the exercise price at $0.50 [4] - The extension is subject to final approval from the Canadian Securities Exchange (CSE) [5] Group 3: Regulatory Compliance - All securities issued in the offering will be subject to a statutory hold period of four months and one day [2] - The securities will not be registered under the United States Securities Act of 1933, and cannot be offered or sold in the U.S. without registration or an exemption [3]

Core Viewpoint - Algernon Pharmaceuticals Inc. has announced an extension of the expiry date for 4,752,969 outstanding warrants, originally set to expire on May 5, 2025, now extended to November 5, 2025, with the exercise price remaining at $0.52 [1][2]. Summary by Sections Warrants Details - The 2023 Warrants were initially set to expire on November 5, 2024, and were previously extended to May 5, 2025, now further extended by six months to November 5, 2025 [2]. - The exercise price of the 2023 Warrants remains unchanged at $0.52 [2]. Regulatory Approval - The Amendment to extend the expiry date is subject to final approval from the Canadian Securities Exchange (CSE), which has granted an exemption from certain requirements to allow the Amendment [3]. - No action is required from the holders of the 2023 Warrants for the Amendment to take effect [3]. Insider Holdings - Out of the 2023 Warrants, 400 have been exercised, with no exercises occurring in the last six months [4]. - Insiders hold 2,018,982 of the 2023 Warrants, representing 42.5% of the total [4]. - The Amendment may be considered a "related party transaction" under Multilateral Instrument 61-101, but is exempt from formal valuation and minority shareholder approval requirements [4]. Company Overview - Algernon Pharmaceuticals is a Canadian clinical stage pharmaceutical development company focused on addressing unmet global medical needs [6]. - The company also has a subsidiary, Algernon NeuroScience, which is advancing a psychedelic program involving a proprietary form of DMT for stroke and traumatic brain injury [6].